Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Loading...
Community
/
United States
/
Materials
/
Bioceres Crop Solutions
Create a narrative
Bioceres Crop Solutions Community
NasdaqGS:BIOX Community
3
Narratives
written by author
0
Comments
on narratives written by author
21
Fair Values set
on narratives written by author
Community Investing Ideas
Bioceres Crop Solutions
Popular
Undervalued
Overvalued
Bioceres Crop Solutions
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Leverage And Argentina Risks Will Impede Performance But Spur Recovery
Key Takeaways International growth in sustainable ag-tech is offset by weak Argentine demand, regional risks, and lingering regulatory threats that could hinder long-term expansion. Shifts toward royalties, value-added integration, and reduced R&D may improve margins eventually but threaten innovation, cash flow, and balance sheet strength in the near term.
View narrative
US$2.5
FV
33.2% undervalued
intrinsic discount
8.80%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
10 days ago
author updated this narrative
Bioceres Crop Solutions
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Sustainable Agriculture And Decarbonization Will Advance HB4 Crop Adoption
Key Takeaways Accelerated adoption across diverse markets and sustainable agriculture trends position Bioceres for strong revenue growth, margin expansion, and premium pricing power. Operational efficiency, asset-light strategies, and broad geographic reach lower risk and support superior, sustained improvements in cash flow and earnings.
View narrative
US$8
FV
79.1% undervalued
intrinsic discount
10.58%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
16 days ago
author updated this narrative
Bioceres Crop Solutions
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Transition To Capital-Light Model And Global Expansion Will Shape Future Success
Key Takeaways Transitioning to a capital-light model and strategic partnerships are expected to reduce costs and boost earnings through higher-margin royalty income and new revenue streams. Geographic expansion and emphasis on high-margin biologicals aim to diversify revenue, improve profit margins, and stabilize earnings amidst domestic volatility.
View narrative
US$6.83
FV
75.6% undervalued
intrinsic discount
9.28%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
12
users have followed this narrative
17 days ago
author updated this narrative